Ontology highlight
ABSTRACT:
SUBMITTER: Recondo G
PROVIDER: S-EPMC4127614 | biostudies-literature | 2014 Aug
REPOSITORIES: biostudies-literature
Recondo Gonzalo G Dìaz Canton Enrique E de la Vega Màximo M Greco Martin M Recondo Gonzalo G Valsecchi Matias E ME
World journal of clinical oncology 20140801 3
During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic ...[more]